Compare Divis Laboratories with Suven Life Sciences - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUVEN LIFE SCIENCES - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUVEN LIFE SCIENCES DIVIS LABORATORIES/
SUVEN LIFE SCIENCES
 
P/E (TTM) x 59.8 -82.0 - View Chart
P/BV x 13.8 1.3 1,069.7% View Chart
Dividend Yield % 0.4 1.8 24.9%  

Financials

 DIVIS LABORATORIES   SUVEN LIFE SCIENCES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
SUVEN LIFE SCIENCES
Mar-19
DIVIS LABORATORIES/
SUVEN LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,639338 485.4%   
Low Rs1,115169 658.2%   
Sales per share (Unadj.) Rs186.352.1 357.4%  
Earnings per share (Unadj.) Rs51.06.8 746.0%  
Cash flow per share (Unadj.) Rs57.38.6 668.8%  
Dividends per share (Unadj.) Rs16.001.50 1,066.7%  
Dividend yield (eoy) %1.20.6 196.4%  
Book value per share (Unadj.) Rs261.865.3 401.0%  
Shares outstanding (eoy) m265.47127.28 208.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.44.9 152.0%   
Avg P/E ratio x27.037.1 72.8%  
P/CF ratio (eoy) x24.029.6 81.2%  
Price / Book Value ratio x5.33.9 135.5%  
Dividend payout %31.422.0 143.0%   
Avg Mkt Cap Rs m365,59232,272 1,132.9%   
No. of employees `00011.81.1 1,094.9%   
Total wages/salary Rs m5,423661 820.1%   
Avg. sales/employee Rs Th4,175.16,132.2 68.1%   
Avg. wages/employee Rs Th457.7611.1 74.9%   
Avg. net profit/employee Rs Th1,141.8803.5 142.1%   
INCOME DATA
Net Sales Rs m49,4636,635 745.5%  
Other income Rs m1,556242 642.3%   
Total revenues Rs m51,0196,877 741.8%   
Gross profit Rs m18,7181,604 1,166.8%  
Depreciation Rs m1,689221 762.9%   
Interest Rs m3538 92.8%   
Profit before tax Rs m18,5511,587 1,168.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023718 699.6%   
Profit after tax Rs m13,527869 1,555.9%  
Gross profit margin %37.824.2 156.5%  
Effective tax rate %27.145.2 59.9%   
Net profit margin %27.313.1 208.7%  
BALANCE SHEET DATA
Current assets Rs m46,5016,232 746.1%   
Current liabilities Rs m8,4681,490 568.3%   
Net working cap to sales %76.971.5 107.6%  
Current ratio x5.54.2 131.3%  
Inventory Days Days13186 151.3%  
Debtors Days Days8683 103.9%  
Net fixed assets Rs m25,7974,043 638.0%   
Share capital Rs m531127 417.0%   
"Free" reserves Rs m68,9628,183 842.8%   
Net worth Rs m69,4938,310 836.3%   
Long term debt Rs m018 0.0%   
Total assets Rs m80,38310,389 773.7%  
Interest coverage x531.043.1 1,231.9%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.6 96.3%   
Return on assets %16.98.7 193.2%  
Return on equity %19.510.5 186.1%  
Return on capital %26.719.5 137.1%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,2385,622 733.5%   
Fx outflow Rs m12,4051,799 689.4%   
Net fx Rs m28,8333,822 754.3%   
CASH FLOW
From Operations Rs m9,543356 2,684.4%  
From Investments Rs m-6,854-279 2,460.2%  
From Financial Activity Rs m-2,459-225 1,092.6%  
Net Cashflow Rs m230-148 -154.9%  

Share Holding

Indian Promoters % 52.0 63.4 82.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.0 -  
FIIs % 19.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 36.5 47.1%  
Shareholders   31,796 37,287 85.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   NOVARTIS  TORRENT PHARMA  STRIDES PHARMA SCIENCE  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)

Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 20, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS